This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NTGN Neon Therapeutics (NTGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Neon Therapeutics Stock (NASDAQ:NTGN) 30 days 90 days 365 days Advanced Chart Get Neon Therapeutics alerts:Sign Up Key Stats Today's Range$3.07▼$3.0750-Day Range$2.77▼$3.0752-Week Range$0.88▼$6.25VolumeN/AAverage Volume516,108 shsMarket Capitalization$88.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Read More Receive NTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTGN Stock News HeadlinesNeon Therapeutics Inc (NTGN_old) Stock Forums - Investing.comJune 29, 2025 | investing.comBCYC Bicycle Therapeutics plcApril 9, 2024 | seekingalpha.com[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.September 2 at 2:00 AM | Golden Portfolio (Ad)NTGN_old Historical DataFebruary 20, 2024 | investing.comNBCO Neon Bloom, Inc.December 22, 2023 | seekingalpha.comMacbeth review – neon-tinted remix plays like a cinematic thrillerMarch 1, 2023 | theguardian.comSee More Headlines NTGN Stock Analysis - Frequently Asked Questions How were Neon Therapeutics' earnings last quarter? Neon Therapeutics Inc (NASDAQ:NTGN) announced its quarterly earnings data on Monday, March, 2nd. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.03. When did Neon Therapeutics IPO? Neon Therapeutics (NTGN) raised $101 million in an IPO on Wednesday, June 27th 2018. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanley, BofA Merrill Lynch and Mizuho Securities served as the underwriters for the IPO and Oppenheimer was co-manager. What other stocks do shareholders of Neon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neon Therapeutics investors own include VBI Vaccines (VBIV), Vaxart (VXRT), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), Aduro Biotech (ADRO) and Altimmune (ALT). Company Calendar Last Earnings3/02/2020Today9/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NTGN CIKN/A Webwww.neontherapeutics.com Phone617-337-4701FaxN/AEmployees102Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-199.09% Return on Assets-137.14% Debt Debt-to-Equity Ratio0.43 Current Ratio1.58 Quick Ratio3.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book6.14Miscellaneous Outstanding Shares28,967,000Free FloatN/AMarket Cap$88.93 million OptionableNot Optionable Beta-0.81 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:NTGN) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Neon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.